Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: vestor who wrote (1179)	5/12/1999 3:06:00 PM
From: Vik Sharma	Respond to of 1837

Great Day for DRMD. The CC was excellent with a lot of upside. Surprised that we did have not gotten a bigger pop. Long @ 4.0

To: vestor who wrote (1179)	5/12/1999 3:13:00 PM
From: vestor	Read Replies (2) \| Respond to of 1837

From the conf call: 1- Approval of BC ANDA in the next few weeks. 2- All three ANDA's approved in the next few weeks. 3- Current market for all DRMD existing and in-pipeline products is billion with growth to 6 - 8 billion in 3 5- yrs. 4- Cardinal will initially have 125 reps. for Cenestin. 5- Pre-book orders for Cenestin are stong and accelerating. 6- Professional promotion begins 6/1. National detailing begins 7/1. 7- Expect approval of 1.25 Cenestin dosage by 4th qtr. 8- Bone mamarrow study to be complete by 11/99. 9- Treatment for Osteo (Cenestin) expected within 24 months. 10- Dillin Reid conf. call 5/25. 11- Merrill Lynch, positive comments, possible coverage soon ?